ArticleEnvironmental science & technology2025
Plastic Additives in Single-Use and Reusable Menstrual Products: Potential Implications for Human Health and the Environment.
Article in Environmental science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perspectives on engineering and biomaterials in tampon design: a review of device-tissue interactions and dysmenorrhea risk.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Menstrual products are essential for half of the world's population during menstruation, but recent studies have found that these products can contain chemicals of concern for human health. The present study detected three classes of plastic additives, phthalates (PAEs), organophosphate esters (OPEs), and alternative plasticizers (APs) in both single-use (sanitary pads, panty liners, and tampons) and reusable (reusable sanitary pads, menstrual underwear, and menstrual cups) menstrual products. Concentrations were between < LOD-42193 ng/g, < LOD-4068 ng/g, and 95.6-13857 ng/g for PAEs, OPEs, and APs, respectively. EDI calculations showed that dermal contact with some menstrual products might be a significant exposure pathway (0.00-3105 ng/kg bw/day for PAEs; 0.00-237 ng/kg bw/day for OPEs; 0.01-7140 ng/kg bw/day for APs, depending on the product). Additionally, risk assessment calculations showed that using some of these products might pose a risk to human health (cancer risk estimates > 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.